<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02660840</url>
  </required_header>
  <id_info>
    <org_study_id>15969A</org_study_id>
    <nct_id>NCT02660840</nct_id>
  </id_info>
  <brief_title>Comparative Study of the Pharmacokinetics and Bioequivalence of Two Flupentixol Formulations</brief_title>
  <official_title>Interventional, Open-label, Randomised, Crossover, Comparative Study of the Pharmacokinetics and Bioequivalence of Two Flupentixol Formulations - Film Coated Tablet (Test Treatment) - 0.5 mg, 1 mg and 5 mg (H. Lundbeck A/S, Denmark) and Coated Tablet (Fluanxol®) - 0.5 mg, 1 mg and 5 mg (H. Lundbeck A/S, Denmark) in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>H. Lundbeck A/S</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>H. Lundbeck A/S</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish bioequivalence between new film-coated tablet formulations of 0.5 mg, 1 mg and 5
      mg flupentixol and the marketed coated tablet formulations of 0.5 mg, 1 mg, and 5 mg
      flupentixol, administered as single doses
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      All subjects will be confined to the clinic from Day -1 (Baseline) until Day 6 (120 hours
      post-dose) for each dosing period. First and second dosing will be separated by a washout
      period of at least 21 days
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2016</start_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The area under the plasma concentration-time curve</measure>
    <time_frame>from 0 to 72 hours post-dose</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>The maximum observed concentration (Cmax)</measure>
    <time_frame>from 0 to 72 hours post-dose</time_frame>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">84</enrollment>
  <condition>Bioequivalence Study in Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>0.5 mg Test, then 0.5 mg reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14 Subjects will receive a 0.5 mg single dose of two different pharmaceutical formulations (first test, then reference)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.5 mg reference, then 0.5 mg Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14 Subjects will receive a 0.5 mg single dose of two different pharmaceutical formulations (first reference, then test)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg Test, then 1 mg reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14 Subjects will receive a 1 mg single dose of two different pharmaceutical formulations (first test, then reference)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1 mg reference, then 1 mg Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14 Subjects will receive a 1 mg single dose of two different pharmaceutical formulations (first reference, then test)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg Test, then 5 mg reference</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14 Subjects will receive a 5 mg single dose of two different pharmaceutical formulations (first test, then reference)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5 mg reference, then 5 mg Test</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>14 Subjects will receive a 5 mg single dose of two different pharmaceutical formulations (first reference, then test)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5 mg Flupentixol film-coated tablet (test treatment)</intervention_name>
    <description>single oral dose, fasted state, day 1 in period 1 or 2</description>
    <arm_group_label>0.5 mg Test, then 0.5 mg reference</arm_group_label>
    <arm_group_label>0.5 mg reference, then 0.5 mg Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 mg Flupentixol film-coated tablet (test treatment)</intervention_name>
    <description>single oral dose, fasted state, day 1 in period 1 or 2</description>
    <arm_group_label>1 mg Test, then 1 mg reference</arm_group_label>
    <arm_group_label>1 mg reference, then 1 mg Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg Flupentixol film-coated tablet (test treatment)</intervention_name>
    <description>single oral dose, fasted state, day 1 in period 1 or 2</description>
    <arm_group_label>5 mg Test, then 5 mg reference</arm_group_label>
    <arm_group_label>5 mg reference, then 5 mg Test</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5 mg Flupentixol coated tablet (reference treatment)</intervention_name>
    <description>single oral dose, fasted state, day 1 in period 1 or 2</description>
    <arm_group_label>0.5 mg Test, then 0.5 mg reference</arm_group_label>
    <arm_group_label>0.5 mg reference, then 0.5 mg Test</arm_group_label>
    <other_name>Fluanxol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1 mg Flupentixol coated tablet (reference treatment)</intervention_name>
    <description>single oral dose, fasted state, day 1 in period 1 or 2</description>
    <arm_group_label>1 mg Test, then 1 mg reference</arm_group_label>
    <arm_group_label>1 mg reference, then 1 mg Test</arm_group_label>
    <other_name>Fluanxol®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5 mg Flupentixol coated tablet (reference treatment)</intervention_name>
    <description>single oral dose, fasted state, day 1 in period 1 or 2</description>
    <arm_group_label>5 mg Test, then 5 mg reference</arm_group_label>
    <arm_group_label>5 mg reference, then 5 mg Test</arm_group_label>
    <other_name>Fluanxol®</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  body mass index (BMI) of ≥18.5 and ≤30 kg/m2

          -  The subject is, in the opinion of the investigator, generally healthy based on medical
             history, physical examination, vital signs, electrocardiogram (ECG), and the results
             of the haematology, clinical chemistry, urinalysis, serology, and other laboratory
             tests.

        Exclusion Criteria:

          -  The subject is pregnant or breastfeeding.

          -  The subject has taken any investigational medicinal products 3 months prior to the
             first dose

          -  The subject has tested positive at the Screening Visit or at the Baseline Visit for
             drugs of abuse (opiates, methadone, cocaine, amphetamines [including ecstasy],
             barbiturates, benzodiazepines, and cannabinoids).

        Other protocol defined inclusion and exclusion criteria may apply
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Email contact via H. Lundbeck A/S</last_name>
    <role>Study Director</role>
    <affiliation>LundbeckClinicalTrials@Lundbeck.com</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>RU801</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 19, 2016</study_first_submitted>
  <study_first_submitted_qc>January 20, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 21, 2016</study_first_posted>
  <last_update_submitted>July 25, 2016</last_update_submitted>
  <last_update_submitted_qc>July 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flupenthixol</mesh_term>
    <mesh_term>Flupenthixol decanoate</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

